Clinical trial · Observational
Transcriptomics and Epigenetics Analysis in Drug-Resistance of Multiple Myeloma
Transcriptomics and Epigenetics Analysis for Biomarkers Identification Involved in Drug-resistance Mechanisms of Multiple Myeloma
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Multiple Myeloma (MM) is the more common hematological neoplastic disease second only to Hodgkin lymphoma. In MM patients, mutated genes are mainly KRAS (23%), NRAS (20%), FAM46C (11%), DIS3 (11%) e TP53 (8%). Epigenetics studies suggested that Changes in histone modifications and DNA methylation pattern, as well as non-coding RNAs (miRNAs) expression are involved in MM development. In particular, it has been shown that the aberrant expression of different miRNAs could discriminate healthy from ill patients. Unfortunately, the main critical issue for an effective treatment of MM is the intrinsic or acquired resistance to pharmacological treatments, due also to a plasmacellular clonal heterogeneity. The prospective study will involve a patient cohort with MGUS, MM smouldering and MM, with the aim to characterize different transcriptional and epigenetic features, also including miRNAs, among MM cells susceptible or resistant to conventional therapies. The final goal is to identify new prognostic and predictive biomarkers that could be used as therapeutic tools to improve clinical targeted therapies.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Multiple Myeloma | Multiple Myeloma | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| ChIP-seq, NGS, ATAC-seq | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (3)
- label
- MGUS
- interventionNames
- Other: ChIP-seq, NGS, ATAC-seq
- label
- MM smouldering
- interventionNames
- Other: ChIP-seq, NGS, ATAC-seq
- label
- Syntomatic MM
- interventionNames
- Other: ChIP-seq, NGS, ATAC-seq
Primary outcomes (2)
- measure
- Transcriptomics variations in treated and non-treated MGUS, MM smouldering and syntomatic MM samples
- timeFrame
- 12 months
- description
- Characterize genetic/epigenetic profile of cells resistant to the treatment sampled from MM patients before and after treatement.
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: \- Compare Transcriptomics and epigenetic profile Exclusion Criteria: * No exclusion criteria
References
Publications (0)
Data not yet available